US Pharma MarketingBioCryst scraps eye candidate to focus on rare diseases
The winding road of BioCryst Pharmaceuticals’ avoralstat has come to an end. The company announced it has concluded development of the plasma kallikrein inhibitor, which was being studied to treat diabetic macular edema.
The company announced it has concluded development of the plasma kallikrein inhibitor, which was being studied to treat diabetic macular edema.
Source: FierceBiotech